GO:0031715 C5L2 anaphylatoxin chemotactic receptor binding

The Gene Ontology term GO:0031715, C5L2 anaphylatoxin chemotactic receptor binding, defines the molecular function of a ligand binding to the C5L2 receptor, also known as C5aR2 or GPR77. This term captures a specific interaction within the complement system, where the anaphylatoxin C5a and its metabolite C5a-desArg serve as ligands. Unlike the classical C5a receptor (C5aR1), C5L2 is a seven-transmembrane receptor that does not couple to G-proteins in the canonical manner, and its binding properties have been a subject of intense investigation. The QuickGO definition states that this function involves binding to a C5L2 anaphylatoxin chemotactic receptor, and the synonym C5L2 anaphylatoxin chemotactic receptor ligand reflects the ligand-centric view of this interaction. Researchers study GO:0031715 to understand how C5L2 modulates inflammatory responses, as it can act as a decoy receptor or a signaling modulator depending on context. The binding of C5a to C5L2 has been implicated in the regulation of macrophage recruitment and adipose tissue function, as demonstrated in C5L2-deficient mice. This molecular function is therefore central to investigations of innate immunity, metabolic homeostasis, and complement-driven diseases. The importance of GO:0031715 extends to translational research, where targeting the C5L2-ligand interaction is explored for therapeutic intervention in inflammatory and metabolic disorders. By defining this binding event at the molecular level, the GO term provides a framework for annotating gene products and designing experiments that probe the role of C5L2 in health and disease.

GO:0031715 is a molecular function term that describes the binding of a ligand to the C5L2 anaphylatoxin chemotactic receptor. In essence, it represents the physical interaction between the C5L2 receptor (also called C5aR2) and its ligands, such as C5a and C5a-desArg, without specifying downstream signaling events. This term is used to annotate gene products that exhibit this binding activity, distinguishing it from binding to other anaphylatoxin receptors like C5aR1.

GO:0031715 is important because it defines a key molecular interaction in the complement system that influences inflammatory and metabolic processes. The binding of anaphylatoxins to C5L2 can modulate immune cell recruitment and adipose tissue function, as shown by increased macrophage infiltration in C5L2-deficient mice. Understanding this binding function helps researchers dissect the dual roles of C5L2 as a potential decoy receptor or signaling modulator, which is critical for developing therapies targeting complement-mediated diseases.

The following genes and proteins are directly involved in or regulate the C5L2 anaphylatoxin chemotactic receptor binding function.

The binding function of GO:0031715 is regulated primarily by the availability of its ligands, C5a and C5a-desArg, which are generated during complement activation. Carboxypeptidase-mediated conversion of C5a to C5a-desArg can shift binding preference toward C5L2, thereby modulating inflammatory responses. Additionally, receptor expression levels and post-translational modifications may influence binding capacity, as suggested by studies in C5L2-deficient mice that display altered macrophage infiltration.

C5L2 anaphylatoxin chemotactic receptor binding has been linked to metabolic and inflammatory disorders. Mice deficient in C5L2 exhibit increased macrophage infiltration in adipose tissue and altered adipose function, suggesting that this binding function normally restrains inflammation and maintains metabolic homeostasis. This implicates GO:0031715 in obesity-related inflammation and insulin resistance.

The complement system, including C5a and its receptors, plays a critical role in sepsis. C5L2 binding may modulate the excessive inflammatory response characteristic of sepsis, although its exact role remains under investigation. Targeting this interaction could provide a strategy to dampen complement-mediated tissue damage.

Anaphylatoxin receptors are implicated in autoimmune conditions such as rheumatoid arthritis. The binding of C5a to C5L2 may influence immune cell recruitment and joint inflammation, making GO:0031715 a potential therapeutic target.

Radioligand binding assays using iodinated C5a or C5a-desArg are standard for measuring the binding affinity and specificity of C5L2. These assays can be performed on membrane preparations from cells expressing recombinant C5L2 or on primary macrophages.

CRISPR-Cas9 technology enables the generation of C5L2 knockout cell lines and mice to study the loss of binding function. Knock-in of tagged C5L2 allows visualization and pull-down of the receptor-ligand complex.

RNA-seq and proteomics can reveal changes in gene expression and protein networks downstream of C5L2 binding, as demonstrated by altered macrophage and adipose tissue profiles in C5L2-deficient mice.

Flow cytometry can quantify C5L2 surface expression and ligand binding on immune cells, while imaging techniques such as confocal microscopy can visualize receptor internalization and trafficking.

Researchers studying C5L2 anaphylatoxin chemotactic receptor binding-related genes often need to determine whether a candidate gene is causally involved in the binding function or its downstream effects. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout and point-mutation models to knock-in reporters and overexpression systems.

GO:0031715, C5L2 anaphylatoxin chemotactic receptor binding, represents a critical molecular interaction in the complement system with implications for inflammation and metabolism. Research using knockout and knock-in models has begun to elucidate how this binding event regulates macrophage infiltration and adipose tissue function. Continued investigation of this binding function will enhance our understanding of complement biology and may lead to new therapies for inflammatory and metabolic diseases.